Finland Cancer Pain Management Market Analysis Report [2022-30]

Finland Cancer Pain Management Market Analysis

$ 3999

Finland's Cancer Pain Management market is projected to grow from $13.69 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030. The main factors driving the growth would be a rising incidence of cancer and government support. The market is segmented by drug type and by disease. Some of the major players include Orion (FIN), Grunenthal Pharma, Sanofi, Pfizer, Teva Pharmaceuticals, and Abbott.

ID: IN10FIHS002 CATEGORY: Healthcare Services GEOGRAPHY: Finland AUTHOR: Neha Davda

Buy Now

Finland Cancer Pain Management Market Executive Summary

Finland's Cancer Pain Management market is projected to grow from $13.69 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. In 2019, Finland's national healthcare spending as a share of GDP was 9.2% or $4,450 per person. Finland's per-capita health spending increased very slowly between 2013 and 2019. It was less than 10% of the EU average in 2019.

Cancer is connected with a number of well-known acute and chronic pain conditions. The complex and sometimes fatal disease known as cancer results in changes to genes that impact vital cell-regulatory proteins. These modifications trigger abnormal cell behavior, which in turn leads to unrestrained cell growth and the subsequent destruction of nearby normal tissues. These tumors compress the body and produce discomfort by pressing on bones, nerves, and other parts of the body. In more severe cases of the disease, cancer pain can also be experienced while receiving active cancer therapy.

Market Dynamics

Market Growth Drivers

Several causes in Finland are causing the market for cancer pain management to expand. Firstly, there is a growing need for efficient pain management therapies due to the rising incidence of cancer. In Finland, cancer is one of the main causes of mortality, and as the population ages, more people are likely to develop the disease. Second, the national health insurance program, which provides coverage for a sizeable section of the population, helps the Finnish government with funding for cancer treatment and pain management. This promotes market expansion and increases cancer patients' access to pain management therapies.

Market Restraints

Some pain management medications have undesirable side effects that might limit their usage and have an effect on the expansion of the cancer pain management market in the country. These adverse effects include nausea, vertigo, urine retention, sleep disturbances, and constipation.

Competitive Landscape

Key Players

Orion (FIN)
Grunenthal Pharma
Sanofi
Pfizer
Teva Pharmaceuticals
Abbott

Notable Recent Deals

July 2022: Orion and Merck entered into an agreement to jointly develop and market ODM-208. Orion will book roughly $220 million of the $290 million upfront payment as revenue at the time of signing, and around $60 million will be set aside to cover Orion's portion of the drug's development expenditures. The Finnish company will be in charge of producing ODM-208 for both clinical and commercial use.

Healthcare Policies and Regulatory Landscape

The Social Insurance Institution (KELA), Finland's comprehensive public healthcare system, offers all people universal coverage. The Ministry of Social Affairs and Health and the Finnish Medicines Agency (FIMEA) is in charge of Finland's policy for treating cancer pain. Both the Finnish pharmaceutical regulations and the laws of the European Union govern the marketing and distribution of cancer pain management medications in Finland. The FIMEA is in charge of the licensing, regulation, and oversight of pharmaceuticals.

Finland has also adopted a number of guidelines and standards for the management of cancer pain in addition to these laws. For instance, recommendations for the management of cancer pain have been developed by Finnish Cancer Organizations and are based on evidence-based practices.

Reimbursement Scenario

In Finland, the Social Insurance Institution (KELA) is mainly responsible for providing reimbursement for cancer pain management. KELA pays for all essential medical procedures and prescription drugs, including those used to relieve cancer pain. KELA oversees the reimbursement procedure for cancer analgesics. The clinical efficacy, safety, and economic value of drugs are assessed. The national reimbursement list, which acts as the foundation for reimbursement by KELA, includes medications that satisfy the requirements for reimbursement.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.